Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | NPY1R | P25929 | 9/20 | 0.40 |
| ▸ | NPY4R | P50391 | 9/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.39 |
| ▸ | NPY2R | P49146 | 3/20 | 0.39 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7598351 | 1.00 | CNR1 (0.42) | CNR1CNR2NPY1RNPY4RNPY5R | |
| SCHEMBL28032819 | 1.00 | CNR1 (0.42) | CNR1CNR2NPY1RNPY4RNPY5R | |
| SCHEMBL7595142 | 0.95 | TRPM8 (0.41) | CNR1CNR2NPY1RTRPM8 | |
| SCHEMBL7595802 | 0.95 | TRPM8 (0.41) | CNR1CNR2NPY1RTRPM8 | |
| SCHEMBL7596200 | 0.92 | TRPM8 (0.37) | CNR1CNR2NPY1RTRPM8 | |
| SCHEMBL7597057 | 0.91 | NPY4R (0.38) | CNR1CNR2NPY1RNPY4RNPY5R | |
| SCHEMBL7597379 | 0.91 | CNR1 (0.43) | CNR1CNR2TRPM8 | |
| SCHEMBL7597777 | 0.91 | CNR1 (0.43) | CNR1CNR2TRPM8 | |
| SCHEMBL7597372 | 0.90 | F2 (0.40) | CNR1CNR2NPY5RTRPM8 | |
| SCHEMBL7600197 | 0.89 | NPY1R (0.48) | CNR1CNR2NPY1RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713780-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-01-18 | — | — | EP | claimed |
| JP-4806628-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| EP-2338490-A2 | Combinations Useful for the Treatment of Neuronal Disorders | Probiodrug AG (DE) | 2011-06-29 | — | — | EP | claimed |
| US-7897633-B2 | Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism | PROBIODRUG AG (DE) | 2011-03-01 | — | — | US | claimed |
| US-20100159032-A1 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | PROBIODRUG AG (DE) | 2010-06-24 | — | — | US | claimed |
| EP-1620091-B1 | INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-03-31 | — | — | EP | claimed |
| US-7655684-B2 | 1-(Urea-, thiourea- and cyanoguanidine-methylene)benzyl)imidaoles, treatment of neuronal disorders, especially Alzheimer's disease, Down Syndrome, Parkinson's disease and Huntington's disease | PROBIODRUG AG (DE) | 2010-02-02 | — | — | US | claimed |
| US-20090018087-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-01-15 | — | — | US | claimed |
| US-7371871-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2008-05-13 | — | — | US | claimed |
| US-7304086-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2007-12-04 | — | — | US | claimed |
| EP-1680120-A2 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | Probiodrug AG (DE) | 2006-07-19 | — | — | EP | claimed |
| EP-1620091-A2 | INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2006-02-01 | — | — | EP | claimed |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | PROBIODRUG AG | 2005-09-29 | — | — | US | claimed |
| WO-2005075436-A2 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2005-08-18 | — | — | WO | claimed |
| US-20050137142-A1 | Combinations useful for the treatment of neuronal disorders | PROBIODRUG AG | 2005-06-23 | — | — | US | claimed |
| WO-2005049027-A2 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | PROBIODRUG AG (DE) | 2005-06-02 | — | — | WO | claimed |
| WO-2004098591-A2 | INHIBITORS OF GLUTAMINYL CYCLASE AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES | PROBIODRUG AG (DE) | 2004-11-18 | — | — | WO | claimed |
| EP-1017672-B1 | NEW NPY ANTAGONISTS | ASTRAZENECA AB (SE) | 2002-11-27 | — | — | EP | claimed |
| EP-1017672-A1 | NEW NPY ANTAGONISTS | AstraZeneca AB (SE) | 2000-07-12 | — | — | EP | claimed |
| WO-1999015498-A1 | NEW NPY ANTAGONISTS | ASTRAZENECA AB (SE) | 1999-04-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018087-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS2, GLS, GLUL | CNR1 1845/4885CNR2 2016/4885NPY1R 280/4885 |
| US-20100159032-A1 | COMBINATIONS USEFUL FOR THE TREATMENT OF NEURONAL DISORDERS | MME, DNPEP, DPP4 | CNR1 1745/4885CNR2 2045/4885NPY1R 18/4885 |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | CNR1 1845/4885CNR2 2016/4885NPY1R 280/4885 |
| US-20050137142-A1 | Combinations useful for the treatment of neuronal disorders | MME, DNPEP, DPP4 | CNR1 1141/4885CNR2 1430/4885NPY1R 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.